We hypothesize that the upregulation of the TGFβ signaling pathway might be implicated in the lower proliferation rate of dasatinib-resistant pre-BCR+/E2A-PBX1+ ALL cells, retaining its growth-inhibitory function. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.